Korean Analysts Retain Optimism For Daewoong Pharmaceutical On Early Pipeline and In-licensing
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Daewoong Pharmaceutical has beefed up its product lineup and increased R&D investment for high-growth therapeutic areas, which has brightened the company's outlook in the eyes of some Korean analysts despite stronger generics competition in 2011
You may also be interested in...
Daewoong Pharmaceutical To In-license Almirall's COPD drug Eklira In Korea
Daewoong signs in-licensing deal just one week before Eklira – a product with a history of clinical setbacks – faces U.S. FDA advisory committee meeting.
Korea's Tightened Regulatory Grip Drops Daewoong and Dong-A Rx Sales In Q2, But OTC Sales Strong
SEOUL - Affected by tightened government surveillance on inappropriate corporate activities, sales of prescription products of some Korean companies shrank in the second quarter while OTC products remained stable
Korea's Tightened Regulatory Grip Drops Daewoong and Dong-A Rx Sales In Q2, But OTC Sales Strong
SEOUL - Affected by tightened government surveillance on inappropriate corporate activities, sales of prescription products of some Korean companies shrank in the second quarter while OTC products remained stable